Skip to main content
. 2013 Apr 2;121(21):4287–4294. doi: 10.1182/blood-2012-12-471680

Table 3.

Association between clinical characteristics, baseline GA measures, and OS among older adults with AML (N = 73)

Baseline characteristics Hazard ratio for mortality (95% CI)
Unadjusted Adjusted*
Clinical and demographic characteristics
 Age (per 10-y change) 1.1 (0.7-1.7) 1.3 (0.8-2.0)
 Education (reference < high school)
  High school 0.9 (0.4-2.0) 0.9 (0.3-2.6)
  College 0.8 (0.4-1.5) 0.8 (0.3-1.8)
 ECOG score (continuous) 1.5 (0.9-2.4) 1.2 (0.7-1.9)
 Hemoglobin (continuous) 0.8 (0.7-1.0) 0.7 (0.6-0.9)
 LDH (≥600) 0.5 (0.2-1.4) 0.6 (0.2-1.5)
 White blood cell count (≥25 000) 0.8 (0.4-1.6) 1.3 (0.6-3.0)
 Cytogenetic risk group (favorable/intermediate) 0.5 (0.3-0.8) 0.3 (0.2-0.7)
 Prior MDS (not present) 0.5 (0.3-0.8) 0.4 (0.2-0.7)
GA measures
 Cognitive impairment (3MS < 77) 2.4 (1.3-4.4) 2.5 (1.2-5.5)
 Depressive symptoms (CES-D score ≥16) 1.4 (0.8-2.5) 1.0 (0.5-2.0)
 Distress (score < 4) 1.2 (0.6-2.1) 1.0 (0.5-1.8)
 IADL impairment (any at the time of treatment) 1.3 (0.7-2.2) 0.8 (0.4-1.6)
 ADL impairment (any at the time of treatment) 1.3 (0.7-2.1) 1.1 (0.5-2.1)
 Mobility impairment (any at the time of treatment) 1.4 (0.7-2.6) 1.0 (0.5-2.1)
 Impaired physical performance (SPPB < 9) 1.9 (1.1-3.4) 2.2 (1.1-4.6)
 Comorbidity burden (HCT-CI > 1) 1.5 (0.9-2.7) 1.2 (0.7-2.2)

One subject with missing cytogenetic risk group data was excluded.

ADL, activities of daily living; IADL, instrumental activities of daily living; LDH, lactate dehydrogenase.

*

Adjusted model includes age, gender, ECOG performance status, cytogenetic risk group, prior MDS, and hemoglobin.